← Back to Search

Behavioral Intervention

Attention Bias Modification for Anxiety

N/A

Recruiting

Research Sponsored by Palo Alto University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

COVID-19 Anxiety Syndrome Scale > 7 and/or COVID-19 related loss

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 105 days

Awards & highlights

Study Summary

"This trial is testing if training people to focus their attention in a certain way can help reduce anxiety and distress related to COVID-19."

Who is the study for?

This trial is for individuals experiencing significant anxiety related to COVID-19, as indicated by a score greater than 7 on the COVID-19 Anxiety Syndrome Scale or those who have suffered a loss due to the pandemic.Check my eligibility

What is being tested?

The study is examining if attention training methods, specifically attention bias modification and attention control training, can alleviate distress and anxiety linked to COVID-19 more effectively than a neutral approach.See study design

What are the potential side effects?

Since this trial involves psychological training interventions rather than medication, side effects are minimal but may include temporary increases in anxiety or discomfort during exercises.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 105 days

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~105 days

This trial's timeline: 3 weeks for screening, Varies for treatment, and 105 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

COVID-19 Anxiety Syndrome Scale

Trial Design

3Treatment groups

Experimental Treatment

Active Control

Placebo Group

Group I: Attention Bias ModificationExperimental Treatment1 Intervention

Group II: Attention Control TrainingActive Control1 Intervention

Group III: Neutral TrainingPlacebo Group1 Intervention

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Attention Bias Modification

2022

N/A

~2130

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

Palo Alto UniversityLead Sponsor

12 Previous Clinical Trials

7,695 Total Patients Enrolled

1 Trials studying Anxiety

63 Patients Enrolled for Anxiety

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are potential participants currently being accepted for this ongoing medical study?

"Indeed, information on clinicaltrials.gov confirms that this medical trial is currently open for patient enrollment. The trial was first made available on February 19th, 2024 and most recently updated on April 1st, 2024. A total of 200 participants are sought from a single research site."

Answered by AI

What is the current number of participants being enlisted for this clinical trial?

"Indeed, the details on clinicaltrials.gov reveal that this trial is actively seeking participants. The study was initially listed on February 19th, 2024, with the latest update made on April 1st, 2024. This research aims to enroll a total of 200 individuals at one designated site."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Attention Training for COVID-19 Related Distress

Mikael Rubin 2024. "Attention Training for COVID-19 Related Distress". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06267313.

All > Sacramento